-
Celebrating 20 Years of Progress in Lung Cancer Research and Treatment
Read time: 5 minutes.
This year marks 20 years since researchers made a key discovery that changed the face of lung cancer research and treatment.
By uncovering EGFR’s role in lung cancer, researchers...
IN THE SPOTLIGHT
-
Brain Mets Basics for NSCLC: What Are Brain Metastases and How Do We Treat Them?
Read time: 2 minutes. Brain metastases (also called brain mets) develop when cancer from somewhere else in the body spreads to the brain. Over time, tumors can become metastatic... -
Screening and Early Detection of Lung Cancer: Highlights from WCLC and ESMO 2024
Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European... -
Cell-Based Therapies for EGFR-Positive NSCLC: Today and Tomorrow
Join us for an interactive Facebook Live discussion to learn how immune cells can be engineered to target EGFR+ NSCLC. This webinar features Jill Feldman and Laura Book, members of... -
Metastatic Non-Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
This year, the first three weeks of September were packed with lung cancer research updates at the World Conference on Lung Cancer (WCLC) from September 7-10 in San Diego followed... -
Eating Healthy on the Mediterranean Diet
Read time: 3 minutes. Oncology dietitian Lori Bumbaco takes us on a culinary journey, exploring why experts consistently rank the Mediterranean diet as the number one choice for... -
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug... -
New Chemotherapy-Free Treatment Combination Approved for EGFR+ Lung Cancer
On August 19, 2024, the US Food and Drug Administration (FDA) approved a new treatment option for people newly diagnosed with locally advanced or metastatic non-small cell lung... -
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are... -
EGFR Virtual Meetup
EGFR patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community.
Finding Balance in Life and Treatment with Marnie Clark
Finding Balance in Life and Treatment with Marnie Clark
The symptoms that led Marnie Clark to her doctor were unusual. Her leg was feeling “weird,” but it was more of an annoyance than something she was concerned about. Then came an issue she couldn’t ignore—her leg was paralyzed, and she couldn’t move it. “The doctor thought it had to be something physically wrong with my leg, but over the previous two years I started to take my health seriously and was working with a personal trainer. I was feeling strong, so it didn’t make sense that I had a…
EGFR+ Lung Cancer: Going Beyond Osimertinib
EGFR+ Lung Cancer: Going Beyond Osimertinib
Learn about what's next once osimertinib stops working in EGFR+ lung cancer. EGFR Resisters co-founders Jill Feldman and Ivy Elkins, and 2021 EGFR Resisters/LUNGevity Foundation awardees Christine Lovly, MD, PhD, and Helena Yu, MD, share updates for the community. This video was recorded on Facebook Live on May 11, 2023.
A Survivor’s Experience with Biomarker Testing and TKI Treatments
A Survivor’s Experience with Biomarker Testing and TKI Treatments
Back in 2013, when Dan Cadigan was first diagnosed with stage III lung cancer, his treatment options were limited to surgery followed by chemotherapy. However, at his one-year follow-up scan, they found nodules in both lungs and he was diagnosed with stage IV recurrent cancer.Normally, it would have meant a return to chemo for treatment.But instead, thanks to a biomarker test that found an epidermal growth factor receptor (EGFR) mutation in the cancer cells, Dan was eligible for a new targeted…
Being a Caregiver for a Parent
Being a Caregiver for a Parent
Being a caregiver for a parent means helping in different ways and playing different roles. For Aimee Yairi, it started when her dad told her that he was having a lingering cough in early 2021. The fear was that he had caught COVID. His primary care physician continued ordering x-rays for her father and prescribing different medications for pneumonia, asthma, and GERD—but resisted sending him to a specialist. Aimee advocated for her father to get a CT scan. And that was when the 7 cm…
Beloved Reporter Goes Public with His Lung Cancer Diagnosis
Beloved Reporter Goes Public with His Lung Cancer Diagnosis
A familiar voice to many in the greater Washington, DC area, Neal Augenstein, a beloved reporter at WTOP radio, joined fellow lung cancer survivor Melinda Ojermark to discuss his experience with lung cancer. Neal has a family history of the disease, so when a persistent cough would not go away, he asked his doctor for screening. A low-dose CT scan revealed that Neal had lung cancer, the same disease that had taken his father's life. Since receiving a Stage IV diagnosis in late-2022,…
Joanne G. Shares her Story
Joanne G. Shares her Story
My lung cancer journey began back in February 2021, by happenstance. I didn’t have any of the classic symptoms, other than I didn’t feel well and I was unusually tired. I reluctantly caved to a trip to the local emergency room for what appeared to be an abdominal hernia or aneurysm.The physician ordered an angio CT scan that revealed a lung mass in the upper lobe of my right lung, which lucky for me was not accompanied by a suspected aortic aneurysm. After many consultations and further testing…
Let Your Voice Be Heard!
Let Your Voice Be Heard!
We are collecting stories from patients, caregivers, friends, and family members! Tell us how lung cancer has affected your life. Email your story to us at support@lungevity.org. Thanks!
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director, Research, discusses innovative research into RET+ NSCLC with patient advocates and the scientist conducting the studies. Panelists include Omaima Salous (diagnosed with RET+ NSCLC and co-founder of The Hamoui Foundation), Dr. Hilary Hammell (diagnosed with RET+ NSCLC and co-chair of RETpositive), and Dr. Tejas Patil (Assistant Professor, University of Colorado). The discussion focuses on Dr. Patil’s RET+ NSCLC research project…